Vivos Therapeutics, Inc. has entered into a collaboration agreement with South Palm Cardiovascular Associates, LLC to form and operate AIM Florida, LLC. The physician-aligned management services organization aims to expand access to integrated diagnostic and therapeutic clinical treatment services for cardiovascular disease patients in Florida who also suffer from obstructive sleep apnea and insomnia.

South Palm Cardiovascular Associates is a Florida-based cardiology practice with approximately 30,000 patients of record. The partnership leverages Vivos Therapeutics' expertise in treating breathing-related sleep disorders and associated chronic health conditions.

The formation of AIM Florida is intended to address the co-morbidity of cardiovascular disease and sleep disorders. By combining resources, the entities seek to provide comprehensive care to patients suffering from both conditions.

Vivos Therapeutics focuses on the treatment of breathing-related sleep disorders, including obstructive sleep apnea and insomnia. The company operates as a medical device and healthcare services provider.

Vivos Therapeutics, Inc. announced that members of its executive management team will participate in The Small Cap Showcase & WTR Insights on June 9, 2026, in New York City. The event serves as a forum for the company to engage with investors and showcase its medical device and healthcare services focused on treating breathing-related sleep disorders.

Kirk Hunstman, CEO of Vivos Therapeutics, is scheduled to deliver a corporate presentation at 11:30 am ET. He will also participate in one-on-one meetings with pre-qualified investors throughout the day.

The Small Cap Showcase & WTR Insights brings together management teams from approximately 20 micro and small-cap companies across various industries. The event aims to facilitate discovery of investment opportunities through presentations, industry insights, and networking.

Access to the presentation details is outlined below:

A live webcast of the presentation will be available online. A replay will be accessible following the event through the Investor Relations section of the Vivos Therapeutics website.

Vivos Therapeutics focuses on developing diagnostic and treatment methods for patients with obstructive sleep apnea (OSA) and snoring. The company's Complete Airway Repositioning and Expansion (CARE) devices are cleared by the U.S. Food and Drug Administration (FDA) for adult patients with all severity levels of OSA and for moderate-to-severe OSA in children ages 6 to 17.